CClinicalTrials.gg
CompletedNCT00854672Updated Apr 6, 2012

Muscle Strength and Exercise Capacity in Sarcoidosis Patients

An observational study in Sarcoidosis, sponsored by Maastricht University Medical Center. Completed at 1 site in Netherlands. Per ClinicalTrials.gov, last updated 2012-04-06.

Sponsored by Maastricht University Medical Center · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
124
Sex
All
01

Study summary

The aim of this study is to examine exercise capacity, muscle strength and fatigue in sarcoidosis. In this longitudinal study the changes in prevalence of exercise intolerance, reduced muscle strength and fatigue will be established in a two-year follow-up. Also the relation between these physical impairments in time and other clinical parameters, such as QOL, will be established.

Read the detailed description

The aim of this study is to examine exercise capacity, muscle strength and fatigue in sarcoidosis. In this longitudinal study the changes in prevalence of exercise intolerance, reduced muscle strength and fatigue will be established in a two-year follow-up. Also the relation between these physical impairments in time and other clinical parameters, such as QOL, will be established.

Study design: sarcoidosis patients referred to the ild care team of outpatient clinic of the department of Respiratory Medicine of the MUMC and also participated in the baseline study between November 2008 and September 2009 will be included in this longitudinal study. A six-minute walk test and peripheral muscle strength measurements (included in the regular clinical work-up of sarcoidosis patients) will be performed under supervision of a physical therapist at the department of physical therapy of the MUMC. Moreover, the patients will be asked to complete the WHOQOL-bref questionnaire and the Fatigue Assessment Scale. A maximum of 124 patients will be included.

02

Conditions studied

  • Sarcoidosis

Browse trials for

Keywords

  • Sarcoidosis
  • muscle strength
  • exercise intolerance
  • QOL
03

In context

Sarcoidosis

279 studies on the registry are indexed under Sarcoidosis; 57 are open to participants now.

This study's enrollment of 124 is close to the median of 125 across 106 observational studies indexed under Sarcoidosis.

Browse Sarcoidosis studies →

Lead sponsor

Maastricht University Medical Center is the lead sponsor of 835 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Sarcoidosis patients referred to the ild care team of the outpatient clinic of the department of Respiratory Medicine of the Maastricht University Medical Centre (MUMC) a tertiary referral center in the Netherlands will be included in this study

Inclusion criteria

  • diagnosed sarcoidosis according to WASOG/ATS/ERS guidelines

Exclusion criteria

Exclusion Criteria:

  • not being able to walk
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
124 participants (actual)

Groups and cohorts

  • sarcoidosis patients

    Sarcoidosis patients referred to the ild care team of the outpatient clinic of the department of Respiratory Medicine of the MUMC and also participated in the baseline study between November 2008 and September 2009 will be included in this study

06

What researchers measure

Primary outcomes

  1. Exercise capacity, muscle strength and fatigue in sarcoidosis: a two-year follow-up study

    6MWD and muscle strength measurements of arm (isometric strength of the elbow flexors) and leg (isokinetic peak torques of the hamstrings and quadriceps) muscles. Questionnaires: WHOQOL-bref and Fatigue Assessment Scale (FAS).

    Time frame: 30 months

07

Study locations

1 site
  • Maastricht University Medical Center
    Maastricht, Netherlands
08

References and documents

Publications

  • Marcellis RG, Lenssen AF, Elfferich MD, De Vries J, Kassim S, Foerster K, Drent M. Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J. 2011 Sep;38(3):628-34. doi: 10.1183/09031936.00117710. Epub 2011 Mar 24. PubMed 21436356 ↗
  • Marcellis RG, Lenssen AF, Kleynen S, De Vries J, Drent M. Exercise capacity, muscle strength, and fatigue in sarcoidosis: a follow-up study. Lung. 2013 Jun;191(3):247-56. doi: 10.1007/s00408-013-9456-6. Epub 2013 Apr 5. PubMed 23558599 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 6, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00854672
Lead sponsor
Maastricht University Medical Center
Collaborators
ild care foundation
Responsible party
marjolein drent (Prof. Marjolein Drent, Maastricht University Medical Center) — Principal investigator
First posted
Mar 3, 2009
Start date
Jan 2009
Primary completion
Aug 2009
Completion
Sep 2011
Last update
Apr 6, 2012

Study contacts

Rik Marcellis, MSc
principal investigator · Maastricht University Medical Center
Marjolein Drent, MD, PhD
study chair · Maastricht University Medical Center and University Maastricht
Ton Lenssen, MSc, PhD
study director · Maastricht UMC and University of Maastricht

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion